Examples of using Mcpp in English and their translations into Portuguese
{-}
-
Colloquial
-
Official
-
Medicine
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
In addition, mCPP is often found in combination with MDMA.
The drug is chiefly available in tablet form, andthe subjective effects of mCPP and MDMA are partially comparable Bossong et al., 2005.
Mcpp-- Matsui's CPP implementation precisely conformed to standards.
It might be assumed that the addition of mCPP is intended to potentiate or ameliorate the effects of MDMA.
MCPP has been described as producing stimulant and hallucinogenic effects similar to those of ecstasy MDMA.
In this context, the 5-HT agonist mCPP exacerbates symptoms in untreated OCD patients and, in rodents.
An example of the need for early-warning information in this area has been the rapid spread of mCPP(1-3-chlorophenyl piperazine) in 2005.
However, as mCPP is not a controlled substance in most Member States, it is likely that seizures are under-reported.
These include ringsubstituted phenethylamines(mostly from the 2C group aswell as TMA-2, 4-MTA, PMMA, etc.), tryptamines(such as DMT, AMT, DIPT and various derivatives) andpiperazinesincluding BZP, mCPP.
Though mCPP is not listed in the UN conventions, it has been subject to control measures in some EU Member States.
Since the EWS started to monitor new(synthetic) drugs in 1997, mCPP has been more widely identified by Member States than any other new psychoactive substance.
In 2009, mCPP still appeared to be the most widely available‘new synthetic drug'¢(161) on the European ecstasy market, either alone or in combination with MDMA.
In a joint report, the EMCDDA and Europol recommended, in line with the provisions of the Council decision,that no formal risk assessment be carried out as there is evidence that mCPP is used in the manufacture of at least one medicinal product.
Of these substances, mCPP had been actively monitored by the EMCDDA and Europol, and BZP had been the subject of a risk assessment in 2007.
Information from the earlywarning system, including reports from users in the Netherlands and seizures in Denmark and the United Kingdom,suggests that the proportion of ecstasy tablets containing mCPP(or piperazines in general) increased markedly in the first half of 2009, possibly exceeding ecstasy tablets containing MDMA.
In 2008, however, mCPP continued to be the most widely available new synthetic drug on the illicit drug market, encountered alone or in combination with MDMA.
The research report includes analysis of 11 global payroll service providers that are'increasingly investing in MCPP platforms' and expanding their reporting and analytical capabilities, interactive mobile support and other advanced employee support features.
Tablets containing mCPP are often designed to look like ecstasy and are almost always traded as such and the drugs are sometimes found in combination.
The EU early-warning system has been monitoring mCPP since 2005, and the EMCDDA and Europol follow developments in this area closely and will produce a report on the market in 2010.
Since 2004, mCPP has been found in 26 Member States(all but Cyprus) and Norway; as such, it is becoming the most widely encountered new psychotropic substance in the EU ever since the European early-warning system monitoring began in 1997.
The emergence of mCPP illustrates the fact that those involved in the production of illicit drugs are constantly looking for innovation in the form of new chemicals that can be introduced to the market- in this case probably to potentiate or modify the effects of MDMA ecstasy.